<DOC>
	<DOCNO>NCT02792192</DOCNO>
	<brief_summary>This Phase Ib/II study design assess safety , tolerability , pharmacokinetics , immunogenicity , patient report outcome ( PROs ) , preliminary anti-tumor activity atezolizumab administer intravenous ( IV ) infusion alone combination intravesical BCG high-risk NMIBC participant .</brief_summary>
	<brief_title>Safety Pharmacology Study Atezolizumab Alone Combination With Bacille Calmette-Guérin ( BCG ) High-risk Non-muscle-invasive Bladder Cancer ( NMIBC ) Participants</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Highrisk histologically confirm nonmuscleinvasive term transitional cell carcinoma ( TCC ) bladder carcinoma insitu ( CIS ) Highrisk NMIBC define follow : BCGunresponsive NMIBC : Persistence highgrade CIS 6 month follow adequate course BCG ; Stage/grade progression 3 month induction BCG ; Recurrence highgrade CIS achieve diseasefree state ( i.e. , Complete Response [ CR ] ) follow induction adequate course BCG occur &lt; 6 month last exposure BCG BCGrelapsing NMIBC : Recurrence highgrade CIS achieve diseasefree state follow induction adequate course BCG occur &gt; /=6 month last exposure BCG Very highrisk ( VHR ) BCGnaïve NMIBC : VHR NMIBC , define least 1 follow : Multiple and/or large ( &gt; 3 cm ) T1 , ( HG/G3 ) tumor T1 , ( HG/G3 ) tumor concurrent CIS ; T1 , G3 CIS prostatic urethra ; Micropapillary variant nonmuscle invasive urothelial carcinoma For BCGunresponsive BCGrelapsing NMIBC , participant must receive adequate course BCG Resection pTa/pT1 papillary disease No prior radiation bladder ; Eastern Cooperative Oncology Group ( ECOG ) performance status less equal ( &lt; /= ) 2 ; Life expectancy equal ( &gt; /= ) 12 week Adequate hematologic endorgan function Creatinine clearance &gt; /=30 mL/min ( calculate use CockcroftGault formula ) For woman childbearing potential : agreement remain abstinent ( refrain heterosexual intercourse ) use contraceptive method result failure rate le ( &lt; ) 1 % per year treatment period least 90 day last dose study drug Tumor tissue biopsy study entry availability archival specimen obtain within 2 month study screen `` Evidence locally advance , metastatic , muscleinvasive , and/or extravesical bladder cancer Any malignancy within 5 year prior Cycle 1 , Day 1 History autoimmune disease , idiopathic pulmonary fibrosis , organize pneumonia ( e.g. , bronchiolitis obliterans ) , druginduced pneumonitis , idiopathic pneumonitis , active pneumonitis Signs symptom infection within 2 week prior first dose study treatment Treatment therapeutic oral IV antibiotic within 2 week prior first dose study treatment Treatment approve anticancer therapy within 3 week prior first dose study treatment Treatment investigational agent participation another clinical trial therapeutic intent within 4 week prior first dose study treatment Pregnant lactate woman , woman intend become pregnant study Prior allogeneic stem cell solid organ transplantation Positive test HIV Active hepatitis B C and/or tuberculosis Severe infection within 4 week prior first dose study treatment Significant cardiovascular disease Major surgical procedure diagnosis within 4 week prior first dose study treatment , anticipation need major surgical procedure course study History prior significant toxicity intolerance BCG require discontinuation treatment History prior systemic BCG infection History immunosuppression , condition associate congenital acquire immune deficiency Concurrent febrile illness , urinary tract infection , gross hematuria Prior treatment CD137 agonists immune checkpoint blockade therapy Treatment systemic immunostimulatory agent within 6 week five halflives drug , whichever short , prior first dose study treatment Treatment systemic immunosuppressive medication within 2 week prior first dose study treatment , anticipated requirement systemic immunosuppressive medication trial ''</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>